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Abstract
Background—Epidemiologic studies have shown a relationship between glycated hemoglobin 
levels and cardiovascular events in patients with type 2 diabetes. We investigated whether 
intensive therapy to target normal glycated hemoglobin levels would reduce cardiovascular events 
in patients with type 2 diabetes who had either established cardiovascular disease or additional 
cardiovascular risk factors.
Methods—In this randomized study, 10,251 patients (mean age, 62.2 years) with a median 
glycated hemoglobin level of 8.1% were assigned to receive intensive therapy (targeting a 
glycated hemoglobin level below 6.0%) or standard therapy (targeting a level from 7.0 to 7.9%). 
Of these patients, 38% were women, and 35% had had a previous cardiovascular event. The 
primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death 
from cardiovascular causes. The finding higher mortality in the intensive-therapy group led to a 
discontinuation of intensive therapy after a mean of 3.5 years of follow-up.
Results—At 1 year, stable median glycated hemoglobin levels of 6.4% and 7.5% were achieved 
in the intensive-therapy group and the standard-therapy group, respectively. During follow-up, the 
primary outcome occurred in 352 patients in the intensive-therapy group, as compared with 371 in 
the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.04; P = 
0.16). At the same time, 257 patients in the intensive-therapy group died, as compared with 203 
patients in the standard-therapy group (hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P = 0.04). 
Hypoglycemia requiring assistance and weight gain of more than 10 kg were more frequent in the 
intensive-therapy group (P<0.001).
Conclusions—As compared with standard therapy, the use of intensive therapy to target normal 
glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce 
major cardiovascular events. These findings identify a previously unrecognized harm of intensive 
glucose lowering in high-risk patients with type 2 diabetes. (ClinicalTrials.gov number, 
NCT00000620.)
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TYPE 2 DIABETES MELLITUS IS A METABOLIC disease that is diagnosed on the basis 
of sustained hyperglycemia. People with type 2 diabetes are at elevated risk for a number of 
serious health problems, including cardiovascular disease, premature death, blindness, 
kidney failure, amputations, fractures, frailty, depression, and cognitive decline.1 In 
prospective epidemiologic studies, the incidence of many of these outcomes is directly 
associated with the degree of hyperglycemia, as measured by the plasma glucose or the 
glycated hemoglobin level, a measure of the mean blood glucose level during the previous 2 
to 3 months. Thus, after adjustment for other risk factors, an increase of 1% in the glycated 
hemoglobin level is associated with an increase of 18% in the risk of cardiovascular events,2 
an increase of 12 to 14% in the risk of death,3,4 and an increase of 37% in the risk of 
retinopathy or renal failure.4
The graded relationship between the glycated hemoglobin level and cardiovascular events 
and death suggested that a therapeutic strategy lower glycated hemoglobin levels might 
reduce these outcomes. This hypothesis was supported by findings from some but not all 
previous clinical trials.1 However, the hypothesis was not explicitly tested in adequately 
powered, randomized trials focusing on cardiovascular outcomes. Nevertheless, data from 
basic science, epidemiologic analysis, and limited trials have been used to support guideline 
recommendations to target near-normal levels of glycated hemoglobin and glucose in 
selected patients with type 2 diabetes mellitus,5-8 despite a paucity of evidence regarding the 
risks and benefits of doing so with currently available therapies.
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial was specifically 
designed to determine whether a therapeutic strategy targeting normal glycated hemoglobin 
levels (i.e., below 6.0%) would reduce the rate of cardiovascular events, as compared with a 
strategy targeting glycated hemoglobin levels from 7.0 to 7.9% in middle-aged and older 
people with type 2 diabetes mellitus and either established cardiovascular disease or 
additional cardiovascular risk factors. The finding of higher mortality in the intensive-
therapy group led to a decision to terminate the intensive regimen in February 2008, 17 
months before the scheduled end of the study. We report the effects of the intensive 
intervention on mortality and the primary composite outcome of major cardiovascular events 
in all patients and in prespecified subgroups.
METHODS
ELIGIBILITY AND STUDY DESIGN
The rationale and design of the trial and a description of the glycemia intervention have been 
reported previously.9,10 Briefly, the ongoing multi-center clinical study, which is sponsored 
by the National Heart, Lung, and Blood Institute (NHLBI), is being conducted in 77 clinical 
centers (aggregated within seven networks) across the United States and Canada. We 
recruited volunteers who had type 2 diabetes mellitus and a glycated hemoglobin level of 
7.5% or more and who either were between the ages of 40 and 79 years and had 
cardiovascular disease or were between the ages of 55 and 79 years and had anatomical 
evidence of significant atherosclerosis, albuminuria, left ventricular hypertrophy, or at least 
two additional risk factors for cardiovascular disease (dyslipidemia, hypertension, current 
status as a smoker, or obesity).9 Key exclusion criteria included frequent or recent serious 
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hypoglycemic events, unwillingness to do home glucose monitoring or inject insulin, a 
body-mass index (the weight in kilograms divided by the square of the height in meters) of 
more than 45, a serum creatinine level of more than 1.5 mg per deciliter (133 μmol per liter), 
or other serious illness.
All 10,251 patients were randomly assigned to receive comprehensive intensive therapy 
targeting a glycated hemoglobin level of less than 6.0% or to receive standard therapy 
targeting a level of 7.0 to 7.9%. With the use of a double two-by-two factorial design, 4733 
patients were randomly assigned to lower their blood pressure by receiving either intensive 
therapy (systolic blood-pressure target, <120 mm Hg) or standard therapy (systolic blood-
pressure target, <140 mm Hg). In addition, 5518 patients were randomly assigned to receive 
either fenofibrate or placebo while maintaining good control of low-density lipoprotein 
cholesterol with simvastatin.11 These blood-pressure and lipid trials are continuing, and 
results regarding them remain masked. The study protocol was approved by the institutional 
review board or ethics committee at each center, as well as by a review panel at the NHLBI. 
All patients provided written informed consent.
Patients received instructional materials and behavioral counseling regarding diabetes care 
and were provided with glucose-lowering medications (from a study-supervised formulary) 
and glucose-monitoring supplies. Any marketed anti-hyperglycemic therapy that was not 
provided by the formulary could also be prescribed to any patient but was not provided by 
study investigators. Therapeutic regimens were individualized at the discretion of the 
investigators and patients on the basis of study-group assignment and the response to 
therapy. Adverse effects of therapy were carefully audited both locally and centrally to 
ensure the safety of the patients.12
Patients in the intensive-therapy group attended monthly visits for the first 4 months and 
then every 2 months thereafter, with at least one interim phone call, with the aim of rapidly 
and safely reducing glycated hemoglobin levels to below 6.0%. Additional visits were 
scheduled as needed to achieve glycemic goals, as described previously.9,10 Patients in the 
standard-therapy group had glycemic-management visits every 4 months.
PRIMARY AND SECONDARY OUTCOMES
The prespecified primary outcome was the first occurrence of nonfatal myocardial infarction 
or nonfatal stroke or death from cardiovascular causes. The latter included death from 
myocardial infarction, heart failure, arrhythmia, invasive cardiovascular interventions, 
cardiovascular causes after noncardiovascular surgery, stroke, unexpected death presumed to 
be from ischemic cardiovascular disease occurring within 24 hours after the onset of 
symptoms, and death from other vascular diseases.9 Death from any cause was one of 
several prespecified secondary outcomes. Study investigators also measured the effect of the 
intervention on microvascular disease, hypoglycemia, cognition, and quality of life, 
although these outcomes are not reported here. Key outcomes were adjudicated by a central 
committee whose members were unaware of study-group assignments on the basis of 
predefined criteria.13 A central laboratory that was unaware of study-group assignments 
analyzed blood for glycated hemoglobin levels. Study investigators outside the coordinating 
center and NHLBI project office were unaware of the accumulating rates of study outcomes.
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SAFETY AND EFFICACY ANALYSES
An independent, 10-member data and safety monitoring committee that was appointed by 
the NHLBI reviewed the interim results approximately every 6 months. The committee’s 
role was to monitor the primary outcome and deaths from any cause, ensure the safety of 
patients, make recommendations to continue or alter the study design, and advise the 
NHLBI if there was clear evidence of benefit or harm. After reviewing mortality trends for 
several months (and as part of a preplanned safety analysis), on January 8, 2008, the 
committee concluded that the harm associated with the increased rate of death from any 
cause in the intensive-therapy group, as compared with that in the standard-therapy group, 
out-weighed any potential benefits and recommended that the intensive regimen be 
discontinued for safety reasons. This recommendation was accepted by the NHLBI. Patients 
were informed of this decision on February 5, 2008, and were subsequently switched to 
standard glycemic therapy. The public was informed of the decision in a press release on 
February 6, 2008. This report is based on data that were submitted to the coordinating center 
through December 10, 2007, and that were used by the data and safety monitoring 
committee to make its recommendation. Some of the adjudications of the causes of death 
were completed after that date.
STATISTICAL ANALYSIS
The study was designed to have a power of 89% to detect a 15% reduction in the rate of the 
primary outcome for patients in the intensive-therapy group, as compared with the standard-
therapy group, assuming a two-sided alpha level of 0.05, a primary-outcome rate of 2.9% 
per year in the standard-therapy group, and a planned average follow-up of approximately 
5.6 years. The original number of patients and power determinations for each study group 
were made under the assumption that the blood-pressure and lipid interventions would 
produce the effect sizes for which they were designed.9
All statistical analyses were conducted at the coordinating center with the use of S-Plus 
software, version 8.0 (Insightful) or SAS software, version 9.1 (SAS Institute). Baseline 
characteristics were compared in the two study groups with the use of chi-square tests and 
two-sample t-tests. At each assessment visit, glycated hemoglobin levels were summarized 
with the use of medians and interquartile ranges. Exposure to glucose-lowering drugs was 
summarized according to study group as the number of patients who received a prescription 
for a medication and the total person-years of prescriptions. The incidence of key safety 
outcomes — including severe hypoglycemia, heart failure, motor vehicle accidents in which 
the patient was the driver, fluid retention, elevated aminotransferase levels, and weight gain 
— were compared with the use of Fisher’s exact test.
Analyses of primary and secondary outcomes were performed with the use of time-to-event 
methods according to the intention-to-treat principle, and occurrences of these outcomes in 
the two study groups were compared with the use of hazard ratios and 95% confidence 
intervals. Two-sided P values were obtained from likelihood-ratio tests from Cox 
proportional-hazards regression analyses. Our inspection of plots of survival estimates 
versus follow-up time indicated that the assumption of proportional hazards for the glycemia 
intervention appeared to be valid. The Cox models contained a term representing study-
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group assignments plus terms accounting for the following prespecified stratifying variables: 
assignment to either the blood-pressure trial or the lipid trial, assignment to the intensive 
blood-pressure intervention in the blood-pressure trial, assignment to receive fibrate in the 
lipid trial, the seven clinical-center networks, and the presence or absence of a previous 
cardiovascular event. An analysis of how sensitive the results were to inclusion of these 
variables as stratifying factors rather than as covariates in the Cox model was also 
performed. Event rates are expressed as the percentage of events per follow-up year, taking 
into account censoring of follow-up data. Kaplan–Meier estimates were used to obtain the 
proportion of patients who had an event during follow-up.
We assessed the consistency of the effect of study-group assignment on total mortality and 
the primary outcome among prespecified subgroups using statistical tests of interaction 
between the treatment effect and the subgroup within the Cox model. We report all nominal 
P values, un-adjusted for the multiplicity associated with the various tests performed for this 
study or monitoring of the primary and mortality end points by the data and safety 
monitoring committee. Since we conducted 15 statistical tests of hypotheses related to 
secondary end points and subgroups, there was a 54% chance (i.e., 1 – [1 – 0.05]15) that at 
least one of these tests would be statistically significant at an alpha level of 0.05, assuming 
independence between tests.
Post hoc exploratory analyses to identify factors associated with higher mortality in the 
intensive-therapy group examined baseline characteristics, hypoglycemic events, risk factors 
for hypoglycemic events, single medications prescribed, combinations of medications 
prescribed, cointerventions, changes in weight, achieved blood pressure, achieved glycated 
hemoglobin levels, and occurrence of a cardiovascular event during follow-up. Detailed 




A total of 10,251 men and women with a mean (±SD) age of 62.2±6.8 years and a median 
glycated hemoglobin level of 8.1% (interquartile range, 7.6 to 8.9) were randomly assigned 
to either the intensive-therapy group or the standard-therapy group (see the figure in the 
Supplementary Appendix, available with the full text of this article at www.nejm.org). 
Approximately 38% of the entire cohort of patients were women. Recruitment occurred in 
two phases: 1174 patients were recruited during a 20-week period from January to June 
2001, and 9077 patients were recruited from February 2003 to October 2005.14 Key baseline 
characteristics were similar in the two study groups (Table 1). The mean duration of follow-
up at the time the data and safety monitoring committee recommended the discontinuation 
of the intensive regimen was 3.5 years (median, 3.4).
The two therapeutic strategies rapidly achieved different glycated hemoglobin levels (Fig. 
1). Within 4 months after randomization, the median glycated hemoglobin level had fallen 
from 8.1% at baseline to 6.7% (interquartile range, 6.2 to 7.2) in the intensive-therapy group 
and to 7.5% (interquartile range, 7.0 to 8.2) in the standard-therapy group. Stable median 
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levels of 6.4% (interquartile range, 6.1 to 7.0) and 7.5% (interquartile range, 7.0 to 8.1), 
respectively, were achieved in the two groups at 1 year and were maintained throughout the 
follow-up period.
The lower glycated hemoglobin levels in the intensive-therapy group were associated with a 
greater exposure to drugs from every class (Table 2). There were also more frequent changes 
in the dose or the number of drugs used. The glucose-lowering regimen was modified by 
adding or removing a drug or by increasing or decreasing the dose of an oral agent or insulin 
(by ≥10% of the previous dose) a mean number of 4.4 times per year in the intensive-
therapy group and 2.0 times per year in the standard-therapy group.
As compared with the standard-therapy group, the intensive-therapy group had significantly 
higher rates of hypoglycemia, weight gain, and fluid retention (Table 3). The annualized rate 
of hypoglycemic episodes requiring medical assistance was 3.1% in the intensive-therapy 
group and 1.0% in the standard-therapy group, and the mean weight gain at 3 years was 3.5 
kg and 0.4 kg in the two groups, respectively. One death in each group was classified as 
probably related to hypoglycemia, according to the adjudicated analysis of causes of death. 
Patients in the two groups had similar exposure to cardiovascular protective interventions 
and had similar changes in non-glycemic characteristics associated with cardiovascular 
events (Table 3). Significantly fewer patients in the intensive-therapy group received an 
angiotensin-converting–enzyme inhibitor than in the standard-therapy group (69.7% vs. 
71.9%, P = 0.02). However, blood-pressure levels were slightly lower in the intensive-
therapy group.
During the intervention period, the primary composite outcome of nonfatal myocardial 
infarction, nonfatal stroke, or death from cardiovascular causes occurred in 723 patients, and 
there were 460 deaths from any cause. In the data reviewed by the data and safety 
monitoring committee, vital status was ascertained in 97.8% of patients within the previous 
12 months; 50 patients (0.5%, including 26 patients in the intensive-therapy group and 24 in 
the standard-therapy group) were lost to follow-up, and 162 patients (1.6%, including 84 in 
the intensive-therapy group and 78 in the standard-therapy group) withdrew consent. The 
mean follow-up time for patients who either withdrew consent or were lost to follow-up was 
1.2 years in the intensive-therapy group and 1.0 year in the standard-therapy group (P = 
0.22). There were fewer occurrences of the composite primary outcome in the intensive-
therapy group, with rates of the primary outcome beginning to separate in the two study 
groups after 3 years (Table 4 and Fig. 2A). This trend was not significant, with rates of 6.9% 
in the intensive-therapy group and 7.2% in the standard-therapy group (hazard ratio, 0.90; 
95% confidence interval [CI], 0.78 to 1.04; P = 0.16). In the intensive-therapy group, the 
rate of nonfatal myocardial infarction was lower than in the standard-therapy group (3.6% 
vs. 4.6%; hazard ratio, 0.76; 95% CI, 0.62 to 0.92; P = 0.004), and the rate of death from 
cardiovascular causes was higher (2.6% vs. 1.8%; hazard ratio, 1.35; 95% CI, 1.04 to 1.76; P 
= 0.02); there was no significant difference in the rate of nonfatal stroke (1.3% vs. 1.2%; 
hazard ratio, 1.06; 95% CI, 0.75 to 1.50; P = 0.74).
The rate of death from any cause was higher in the intensive-therapy group than in the 
standard-therapy group (5.0% vs. 4.0%; hazard ratio, 1.22; 95% CI, 1.01 to 1.46; P = 0.04). 
Page 6













In sensitivity analyses of the Cox model for death from any cause that included variables as 
stratifying factors rather than as covariates, the estimated hazard ratio for mortality in the 
intensive-therapy group, as compared with that in the standard-therapy group, was stable to 
the second decimal place. Rates of death in the two study groups began to separate after 1 
year, and the differences persisted throughout the follow-up period (Fig. 2B). The effect on 
mortality was consistent within the subgroups with no evidence of heterogeneity (Fig. 3) and 
persisted in models adjusting for differences in the receipt of medications for blood pressure 
and lipids.
For the primary outcome, there was some evidence of heterogeneity among prespecified 
subgroups, which suggested that patients in the intensive-therapy group who had not had a 
cardiovascular event before randomization (P for interaction = 0.04) or whose baseline 
glycated hemoglobin level was 8.0% or less (P for interaction = 0.03) may have had fewer 
fatal or nonfatal cardiovascular events than did patients in the standard-therapy group (Fig. 
3). Preliminary nonprespecified exploratory analyses of episodes of severe hypoglycemia 
after randomization and differences in the use of drugs (including rosiglita-zone), weight 
change, and other factors did not identify an explanation for the mortality finding.
DISCUSSION
We conducted this study because previous clinical trials had not established the effects of 
intensive glucose lowering on cardiovascular events or mortality in patients with type 2 
diabetes mellitus. For example, in the United Kingdom Prospective Diabetes Study,15 an 
intensive glucose-lowering regimen significantly reduced a composite outcome of seven 
diabetes-related events, as compared with conventional therapy. However, the effects on 
cardiovascular events and mortality were not significant. Conversely, in the Veterans Affairs 
Diabetes Feasibility Trial,16 intensive glucose lowering was associated with a nonsignificant 
increase in cardiovascular events and no difference in mortality, and in the University Group 
Diabetes Program,17,18 the group that received a sulfonylurea (tolbutamide) had higher 
mortality.
Our findings indicate that a comprehensive, customized, therapeutic strategy targeting 
glycated hemoglobin levels below 6.0% increased the rate of death from any cause after a 
mean of 3.5 years, as compared with a strategy targeting levels of 7.0 to 7.9% in patients 
with a median glycated hemoglobin level of 8.1% and either previous cardiovascular events 
or multiple cardiovascular risk factors. Patients in both groups had lower mortality than 
reported in epidemiologic studies of similar patients.19,20 However, as compared with the 
standard-therapy group, the intensive-therapy group had a relative increase in mortality of 
22% and an absolute increase of 1.0% during this follow-up period, with similar differences 
in death from cardiovascular causes. This increase in mortality is equivalent to one extra 
death for every 95 patients who were treated for 3.5 years.
This study was not designed to test the components of the intervention strategy. Analyses 
that we have performed to date have not identified and clear explanation for this higher 
mortality. In the intensive-therapy group, a median glycated hemoglobin level of 6.4% was 
rapidly achieved and maintained by a combination of behavioral and pharmacologic 
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approaches. The standard-therapy group had fewer study visits and used fewer drugs and 
drug combinations. Thus, the higher rate of death in the intensive-therapy group may be 
related to factors associated with the various strategies. These factors include but are not 
limited to differences in the achieved glycated hemoglobin level of 6.4% in the intensive-
therapy group, as compared with 7.5% in the standard-therapy group; in the magnitude of 
the reduction in glycated hemoglobin levels in the two study groups; in the speed of the 
reduction in glycated hemoglobin levels, with reductions of approximately 1.4% in the 
intensive-therapy group and 0.6% in the standard-therapy group within the first 4 months 
after randomization; in changes in drug regimens and in the rate of hypoglycemia; in 
adverse effects due to an undetected interaction of the various drug classes used at high 
doses; or in some combination of these or many other possibilities, perhaps in combination 
with the clinical characteristics of the patients in the study.
Differences in mortality emerged 1 year to 2 years after randomization. It is notable that 
after about 3 years, a nonsignificant decrease in the rate of the primary outcome emerged in 
the intensive-therapy group (Fig. 2A), due to significantly fewer nonfatal myocardial 
infarctions, despite more deaths from cardiovascular causes and a similar number of strokes 
(Table 4). These patterns with respect to mortality and the primary outcome suggest that if 
there is any benefit associated with intensive glucose lowering, it may take several years to 
emerge, during which time there is an increased risk of death. This intriguing possibility can 
be answered only by further research.
The strengths of our study include the random assignment of patients to study groups and 
follow-up of a large number of high-risk patients according to a common protocol, a high 
rate of follow-up, achievement and maintenance of an absolute difference in glycated 
hemoglobin levels of 1.1% for 3.5 years, implementation within clinics that routinely treat 
patients in the community, adjudication of outcomes by a committee unaware of study-
group assignment, a factorial design in which blood-pressure and lipid interventions 
continue to be tested, and safety auditing by an independent committee. However, our study 
did not address the risks and benefits of various approaches to lowering glycated 
hemoglobin levels (including what rate of glucose lowering is optimal), the prevention of 
increased glycated hemoglobin levels in patients with type 2 diabetes mellitus who have 
glycated hemoglobin levels below 7.5%, the prevention of diabetes altogether, and the 
lowering of glycated hemoglobin levels in people who do not have cardio-vascular disease 
or additional cardiovascular risk factors. Indeed, the suggestion of a greater benefit in the 
primary outcome for patients with a lower glycated hemoglobin level or those without 
cardiovascular disease raises the possibility that certain subgroups of patients may benefit 
from intensive glucose lowering. However, our study was not designed to test these 
possibilities. Finally, glucose-lowering strategies were adjusted for each patient in an open 
fashion on the basis of their study-group assignment, their subsequent glycemic response to 
a drug or drug combination, and the development of clinical symptoms, such as 
hypoglycemia. This linkage of the study-group assignment to post-randomization exposures 
means that analyses to discern which aspects of the therapeutic strategy contributed to the 
observed outcomes were unlikely to clearly identify or exclude a cause. Thus, 
nonprespecified analyses of possible causes of the higher mortality in the intensive-therapy 
group can be only exploratory and require prospective testing.
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Follow-up of the patients after they were switched from intensive therapy to standard 
therapy may provide crucial information regarding the long-term rates of death and 
cardiovascular events after a 3.5-year period of intensive therapy. Other trials investigating 
the long-term outcome of intensive glucose lowering21-25 will report the effect of a variety 
of therapeutic approaches on mortality and cardiovascular events in patients with type 2 
diabetes mellitus and a range of clinical characteristics. Regardless of the results of these 
other trials, our study has identified a previously unrecognized harm of intensive glucose 
lowering in high-risk patients with type 2 diabetes mellitus and high glycated hemoglobin 
levels. This harm may be due either to the approach used for rapidly lowering glycated 
hemoglobin levels or to the levels that were achieved. Our findings highlight the importance 
of conducting trials with sufficient statistical power to assess commonly used approaches on 
clinically relevant outcomes.
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Gibbons,* C. Kovacs, B. Murphy, R. Smart, S. Varghese. University of Alberta, Edmonton: 
L. Mereu, E. Ryan, P. Senior, P. Kirkland, J. Abe,* K. Dalton, W. Gendall, J. Germsheid,* 
D. Hartman,* A. Jeffrys,* C. MacDonald, N. Makhani, S. Mawani,* F. Morales, B. Paty,* 
M. Pick,* B. Schwanke, A. Stark, M. Tennant, S. Varma,* P. Werbiski-Wood, B. 
Woloschuk, W. Zimmerman.* Centre de Recherche Clinique de Laval, Laval, QC: A. 
Bélanger, S. Gauthier, G. Bahsali, C. Barbeau, E. Caponi, R. Duchesne,* R. Dumas, P. 
Gauthier, J. Girouard, N. Kandalaft, M. Labbé, J. Palardy, M. Pilon, J. Raymond, A. 
Schiffrin. St. Joseph’s Health Care London, London, ON: I. Hramiak, S. Tereschyn, M. 
Driscoll, M. Gehring, J. Gonder, C. Lincoln, W. McBeth, C. McDonald, T. McDonald,* P. 
Pauli,* T. Paul, S. Powers,* N. Ronald, V. Trinh, L. Vancer, G. Walsh.* Ottawa Hospital, 
Division of Endocrinology and Metabolism, Ottawa: H. Lochnan, T.C. Ooi, J. Maranger, R. 
Bate,* L. Bradley,* R. Buhrmann, M. Cyr,* C. Gilchrist, B. Hanlon, M. Harley, K. Jay,* T. 
Leech, J. Malcolm, M. McLean,* E. Parker, R. Sigal,* K. Sullivan. Royal Victoria Hospital, 
Montreal: J.F. Yale, S.A. Segal, N. Renouf, N. Allaire,* M.A.M.A. Alawadhi,* B. Belfer,* 
D.W. Blank, F. Bouchard, S. Buoy-Phang,* J. Carter, L. Coppin,* D. Dalpe,* I. Delpech,* 
P.M. Doran, F. Emmian,* S. Fortin,* N. Garfield, M. Gosselin,* S. Horan,* M. Kalergis,* 
S. Koutelias,* C. Légaré, A. Lombardo, J.A. Morais, M. Quigley, N. Renouf, C. Riopel,* S. 
Riopel, J.A. Rivera, G. Rochon,* M. Roy, M. Salera,* M.H. Sherman, M. Shingler, H.E. 
Staples,* L. Ulyatt,* Z. Yared.* St. Michael’s Hospital, Toronto: L.A. Leiter, G. Booth, L. 
Sparrow, H. Choi, D.C. Bedard, A. Berger, L.A. Berndl, A. Cheng,* V. Evalmplev,* J. 
Goguen, A. Hanna, R.G. Josse, J.A. Kalas, S. Perry, M. Pike.* Vancouver General Hospital, 
Vancouver, BC: T. Elliott, K. Dawson, J. Kong, M. Inducil, R. Al Amoudi,* T. Broughton,* 
L. Hall,* B. Harrison,* N. Hirvi,* R. Lee,* E. Norman,* B. Paty, M. Potter, D. Stevenson, 
A. Vafadaran. Health Sciences Centre Diabetes Research Group, Winnipeg, MB: V. Woo, 
L. Berard, T. Anderlic, K. Austman, A. Bernard, D. Catte,* P. Darvill, D. Hak, K. 
Hutchison, L. Janzen, T. Klopak, C. Mandock, M. Mathen, S. Mawani,* A. Mawani,* L. 
Murphy,* G. Nyomba, B. Penner, S. Pockett, S. Russell, F. Stockl, J. Studney,* R. Sukkau. 
Queen Elizabeth II Health Sciences Centre, Halifax, NS: C. Abbott, E. Ur, M. Yuille, M. 
Archibald,* A. Cruess, N. Davis, H. Fong,* S. Frizzell,* B. Hanway,* A. Hoskin-Mott, A. 
Imran, C. Ingraham,* G. McCarthy, H. Murdock,* T. Palmer, A.M. Patterson,* T. Ransom, 
D. Shu,* J. Tuttle. Western Clinical Center Network: University of Washington, Seattle: 
J.L. Probstfield, C. Kingry, A.S. Line, M.A. Corson, R. Knopp, E. Lipkin, M.D. Sullivan, J. 
Johnson, C. Griswold, K. Liebert, A. Brown,* D. Juliano,* E.M. Kurashige,* S. Moberg.* 
Western Clinical Sites: Northridge Hospital Medical Center, Cardiovascular Center, 
Northridge, CA: K. Ariani, K. Karunaratne, M. Azizad, C. Chow, H. Gutierrez, J. 
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Partamian, J. Toven, J. Mular,* S. Sanders.* White Memorial Medical Center, Clinical 
Hypertension Services, Los Angeles: L.J. Haywood, V. Kamdar, D.L. DeQuattro, L. Wang, 
Z. Song, C. Miller, L. Becerra, A. Qi Cai, C. Pruitt, V. DeQuattro.† University of 
Washington Medical Center at Roosevelt, Family Medical Center, Seattle: R. Failor, A. 
Ellsworth, N. Jackson, C. Miller, D. Britt, S. Dobie, I. Hirsch, D. Khakpour, R. Quaempts, 
W. Stoffel, T. Wilcox, W. Neighbor,* K. Cappocia.* Idaho State University, Department of 
Family Medicine, Pocatello: R. Force, M. Macdonald, S. Lusk, C. Liday, E. Borzadek, S. 
Koester, T. Pettinger, R. Solbrig, C. Waldron, K. Pettingill,* W. Woodhouse,* B. Hoover.* 
Naval Medical Center San Diego, Cardiology Division, San Diego, CA: P.E. Linz, P.V. 
Pepper, J. Kozlowski, C. Chase, D. Samuelson, P. Gutierrez, C. Gonzales, M. Engle,* J. 
Coopersmith,* S. Griffin,* R. Lammers,* J. Leon.* Oregon Health & Science University, 
Section of Diabetes, Portland: M.C. Riddle, K.A. Hanavan, P.A. McDaniel, R. Swift, A.J. 
Ahmann, S.C. Gammell-Matthews, D.M. Karl, V. Burden, B. MacNeil, M. MacMurray, J. 
Weiss, C. Carlson,* S.K. DesRochers,* D. Negreanu,* E.A. Stephens.* Washington State 
University, Spokane: C. Wysham, D. Weeks, L. Kuntsmann, L. Maxwell, S. Yedinak, H. 
Pena,* J. White.* Kaiser Endocrine Clinic, San Diego, CA: J. Dudl, L. Lyons, B. House, M. 
Murray, P. Wu, A. Palma, S. Briere, T. Wilson, D. Becker,* K. Harden,* C. Hawley,* R. 
Stevenson.* Whittier Institute for Diabetes, Clinical Trials Department, La Jolla, CA: G. 
Dailey, M. Baron, A. Gianella, M. Jacobson, E. Farro, A. Philis-Tsimikas, A. Banares, A. 
Bravo-Medina, J. Horne,* E. Esquer,* R. Morrissey.* Minnesota–Iowa Clinical Center 
Network: Berman Center for Outcomes and Clinical Research, Minneapolis: R.H. Grimm, 
Jr., B.R. Kirpach, M.M. Bartkoske, C.M. Boyce,* N. Druckman,* A.M. Gillett,* J.A. Levin, 
G.J. Livingston, A.M. Murray, H. Wood,* HealthPartners Research Foundation, 
Minneapolis: K.L. Margolis. Minnesota–Iowa Clinical Sites: Berman Center Clinic, 
Minneapolis: S. Kempainen, M. Madden, M. Tariq Fareed,* K. Hall,* R. Moor, K. Wood. 
International Diabetes Center, Minneapolis: R. Bergenstal, R. Cuddihy, B. Davick, J. 
Hokanson,* M. Johnson, D. Kendall,* M. Lausch, S. List, A. Monk, R. Robinson,* K. 
Smith,* D. Whipple, G. Damberg, R. Hahn,* V. Koenig, M. Magadan, S. Sabin-Smith,* P. 
Stewart, E. Strock, D. Peremislov, K. Gunyou, R. Passi. University of Minnesota, 
Minneapolis: E.R. Seaquist, M.V. Mech, L.E. Benedict,* D.J. Demmon,* A.F. Kumar, S.M. 
Martinson,* S.A. Miller, C. Pease,* J.P. Rao,* J.B. Redmon, J.E. Swanson,† J.K. Wimmer.* 
University of Minnesota, Phalen Village Clinic, St. Paul: K. Peterson, L.A. Seaquist, C. 
Boese,* M. Cruciani, E. Dodds, F. Parenteau Ek,* J.L. Feldman, P. Fontaine, C.J. Lange, 
T.J. Mendenhall,* A.M. Peterson, A. Rudelt, T.M. Schrock,* D.P. Spielman,* S. Velasco,* 
J.C. Weinhandl. Riverside Health Partners Clinic, Department of Endocrinology, 
Minneapolis: J.M. Sperl-Hillen, P.J. O’Connor, M.E. Busch, A. Chung, B.K. Klein, N. 
Krugen, T. Bunkers-Lawson,* H.L. Ekstrom,* H.S. Gunderson,* B.M. Johnson,* J.H. 
MacIndoe,* D.J. Prewedo,* J.L. Rawl,* C.M. Roethke,* Mary Spencer. University of Iowa, 
Health Care Diabetes Clinical Research and Programs, Iowa City: W.I. Sivitz, S.M. 
Wayson, T.A. Lower,* L. Larson, L.A. Ahrens,* M. Bayless, S.E. Beck,* J. Chahal, C. 
Chenard, G.C. Doelle, V.M. Guzman, U.M. Kabadi,* K.A. Ochs,* A. Rahhal, R.G. 
Spanheimer,* L. Snetselaar,* K. Smith,* D. Wells. Ohio–Michigan Clinical Center 
Network: Case Western Reserve University, Division of Clinical and Molecular 
Endocrinology, Cleveland: F. Ismail-Beigi, S. Genuth, M. Thibonnier,* L. Vargo,* C. 
Kelly,* T. Bongorno,* A. Dolish,* L. Pavlik, M. Tiktin, S. Isteitieh. Ohio–Michigan 
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Clinical Sites: University Hospitals of Cleveland, Division of Endocrinology, and 
University Hospitals Westlake Medical, Cleveland: F. Ismail-Beigi, A. Krikorian, L. Moore, 
L. Richardson, E. Coles-Herman, K. Yee, J. Frankino, M. Jing, A. Sood, L. Hustak,* M. 
Julius,* L. Pavlik,* T. Ross,* L. Long,* W. Schwing,* M. Tiktin,* M.K. Sullivan,* L. 
Strauss,* K. Behm,* F. Eskandari,* C. Hall,* D. Hayes,* K. Horowitz, S. Isteitieh,* Z. 
Madhun,* E. Seeholzer,* J. Shina,* H. Taylor,* A. Schnall,* S. Huang, M. Heeg, J. Tang, J. 
Belkin,* M.S. Lee,* T. Joly.* St. Vincent Charity Hospital, Lipid Research Center, 
Cleveland: L.S. Sadler, M. Griffith,* A. Hornsby,* K. Klyn, E. Ospelt, L. Long, M. 
DeSmit,* P. McCann, N.P. Schmidt,* C. Gottfried, T. Kulow, J. Zaletal, M.S. Kapadia. 
University Suburban Health Center, South Euclid, OH: A.M. Schnall, L. Dragmen, R. 
Ellert,* J. Smith, J. Leksan, T. Sussman, S. Huang, M. Heeg, J. Tang, J. Belkin,* M.S. Lee,* 
T. Joly.* Cleveland Veterans Affairs (VA) Medical Center, Department of Medicine, and 
Ravenna Community Based Outpatient Clinic, Cleveland: F. Ismail-Beigi, L. Hustak, M. 
Julius,* W. Schwing, M. Tiktin,* J. Anselmo,* F. Eskandari,* S. Daeumeyer,* C. Hall, D. 
Hayes,* K. Horowitz, S. Isteitieh,* C. Johnson,* E. Kern, M.A. Richmond,* L. Richardson, 
K. Roberts,* J. Shina,* A. Sood, P. Suhan,* H. Taylor, S. Watts,* J. Martin, L. Moore,* B. 
Burtch,* S. Ober, G.J. Strauss, A. Leone, J. Belkin,* S. Huang,* K. Frank,* D. Stephens,* 
M.S. Lee,* T. Joly.* The Cleveland Clinic Foundation, Cleveland: B.J. Hoogwerf, J. 
Brakeman, M. Matzinger,* J. Newsome,* J. Becker,* S. Bizjack,* B. Clingman,* S. Curtas, 
G. Depietro,* R. Ellert,* C. Horner, G. Bunae,* A. Hamrahian,* A. Hawkins, T. Head, S. 
Iannica, L. Jones, P. Kaiser, R. McCoy, A. Mehta, L. Olansky, A. Orasko, S. Reddy,* D. 
Ross,* L. Shockley,* E. Siraj,* M. Williams,* R. Zimmerman. Your Diabetes Endocrine 
Nutrition Group, Mentor, OH: D. Weiss, K.A. Fagan, T.M. Hanslik, J. Farrell, P. Brys, M. 
Oligny, K. Prokop, K. Lenardic, T. Karapanzcik, S. Huang, M. Heeg, J. Tang, J. Belkin,* 
M.S. Lee,* T. Joly.* Medical University of Ohio, Department of Medicine, Ruppert Health 
Center, Toledo: B. Akpunonu, R. Franco-Saenz,† J. Gilmore, M. Gilmore, L. Godfrey, P. 
Ross, B. Bauer, M. Chrisstie,* A. Lopez, P. Mulrow, C. Peters,* R. Pop-Busui,* J. Roman,* 
C. Smith,* J. Bick,* Z. Blust,* P.T. Nelsen, D. Marcus.* The Ohio State University Medical 
Center, Division of Endocrinology, Diabetes and Metabolism, Columbus: K. Osei, E.A. 
Dziengelewski,* H. Breedlove, D. Boland,* C. Casey Boyer, S. Cataland, P.A. Green, J.E. 
Irwin, D.P. Schuster, J.L. Varga-Spangler, T. Bowles, K. Weiland, K. Arnold, T. Evans,* J. 
Bouttamy, A. Letson, E. Craig, F. Davidorf. University of Cincinnati/VA Medical Center, 
Research Service, Cincinnati: R.M. Cohen, K. Burton, J. Craig, B. Carter,* J. Harrer,* R. 
Hurd,* D. Lopez-Stickney,* C. Pritchard,* A. Pfefferman,* B.A. Ramlo-Halsted,* C. 
McCormick, C. Riley, M. Strominger,* A. Knittel, G. Groff, C. Bailey, A. Howald, N. 
Anderson, J. Laver Bierschbach, M. Tyzinski,* B. Smith,* S. Krug, V. Hershberger,* R.K. 
Hutchins,* L.A. Raymond.* Henry Ford Health System–New Center One, Detroit: D.M. 
Kahkonen,* T. Cushman, M. Roman, A.M. Stys, A. Thomas, K. White, M. Austin,* C. 
Chatterton, J.K. Francis,* C. Jones,* D. Kruger, A. McLellan,* F. Whitehouse, E. Higgins,* 
S. Levy, A. Schoenherr,* P. Edwards. Grunberger Diabetes Institute, Bloomfield Hills, MI: 
G. Grunberger, L.C. Aman,* A.H. Bandagi,* K.M. Russell, C. Tucker, Y. Abidova, A. 
Amirikia. Northeastern Clinical Center Network: Columbia University College of 
Physicians and Surgeons, New York: J.T. Bigger, C.R. Lopez-Jimenez, R. Bornholdt, L. 
Busacca, H.N. Ginsberg, P. Gonzales, D. Gosh,* P. Love,† A. Kosok,* E. Robinson,* R. 
Steinman, C. Watson, G. Reyes. Northeastern Clinical Sites: Jacobi Medical Center, 
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Bronx, NY: U.K. Schubart, M. Mendoza, G. Goswami, A. Laufer,* J. Russo, N. Vincenty. 
Albert Einstein General Clinical Research Center, Bronx, NY: M.H. Alderman, L. Carroll, 
M.J. Sanguily, J.U. Gorkin, A.C. Mayer, L. Ramos, V. Sessoms, A. Fritts Stewart.* Cornell 
Internal Medicine Associates, New York: D. Brillon, J. Cordero, M.A. Richardson, E. Wei, 
F. Ganz, B.R. Meyer, J. Paley,* S. Anderson,* C. Charles,* A. Dwoskin,* R. Chiong, K. 
Hyams. The Diabetes Care and Information Center of New York, Flushing: D.L. Lorber, T. 
Arenstein, P. Depree, A.A. Elmorsy,* J.M. Wendel, L.L. Zintl, P. August, M. Beck,* M.D. 
Goldberg, M.J. Hofacker,* M. Marotta-Kollarus,* E.J.L. Ocampo, C.A. Resta, J.M. Tibaldi. 
The Cooper Health System, Cherry Hill, NJ: A. Bastien,* S. Grudzinski, P. Niblack, L. 
Abreu, T. Brobyn, K. Brown,* M. Casale,* D. Dougherty,* G. Haddad, K. Heintz, M. 
Kelly,* D. Linneman,* C. Olivia, M.A. Salvador,* P. Zee,* D. Hyman. Great Lakes Medical 
Clinic Research, Westfield, NY: D.F. Brautigam, R. Fischer, J.M. Chiarot, D.M. Scharf, B. 
Nunn,* J. Carlson, C. Flanders,* M.R. Hagen, S. Newman, T.A. Gordon. Naomi Berrie 
Diabetes Center, New York: R. Goland, C.H. Tuck,† P. Kringas, J. Hey-Hadavi,* J. 
Montes,* J. Vargas-Jerez, J. Salas-Spiegel. Ambulatory Care Network at Columbia 
University, New York: A. Getaneh, J. Ramirez,* E.F. Vasquez,* G. Kranwinkel. Irving 
Diabetes Research Unit, New York: D.S. Donovan, G. Febres,* C. Hernandez,* M.A. 
Jonaitis, L. Mesa. State University of New York Downstate Medical Center, Brooklyn: 
M.A. Banerji, M. Norton, P. Patel, V. Daly, S. Hirsch, C. Jazmin, R. Khillan, D. Mendonca, 
A. Relingado, E. Sandoval, M. Tiewala. Kings County, Brooklyn, NY: M.A. Banerji, M. 
Norton, P. Patel, V. Daly, S. Hirsch, C. Jazmin, R. Khillan, D. Mendonca, A. Relingado, E. 
Sandoval, M. Tiewala. Southeastern Clinical Center Network: Wake Forest University 
School of Medicine, Department of Public Health Sciences, Winston-Salem, NC: D.C. Goff, 
Jr., J.H. Summerson, L. Crago, C.S. Blackwell,* A. Bertoni,* R.L. Blaine, J.K. Kirk, R.L. 
Spach, J. Williamson, J. Calles, J. Katula, D.B. Wishnietsky.* Southeastern Clinical Sites: 
Duke University Medical Center, Durham, NC: M.N. Feinglos, J. Jones, M.B. Mason, M.A. 
Furst, W.J. Bean,* G. Gedon-Lipscomb, J.B. Green, T. Parham,* B.M. Satterwhite,* C.R. 
Thacker. Constant Care, Inc., Valdosta, GA: D. Padhiar, R. Noel,* N. Padhiar, S. West,* J. 
Braden, A. Francis.* Wake Forest University School of Medicine, Department of Geriatrics/
Gerontology, Winston-Salem, NC: H.H. Atkinson, M. Dibari,* J. Allen, J. Stanfield, T. 
Delvalle-Fagan, L.J. Gordineer, L. Gordon, M. Gordon,* S.L. Smith,* H. Yates.* 
Downtown Health Plaza, Winston-Salem, NC: C.F. Pedley, G. Zurek, M. Baird, B. Dunn,* 
W. Kinder,* S. Mauney. University of North Carolina, Diabetes Care Center, Chapel Hill: 
J.B. Buse, M.D. Duclos, R.E. Kirby,* J.F. Largay, N.M. McDermott,* A. Goley, S.S. 
Braithwaite, M. Busby, J.M. Dostou, E.A. Fasy,* D.C. Kelly,* B. MacIntosh, C.E. Metz,* J. 
Jeffries, D. Rubin.* Holston Medical Group, Kingsport, TN: J.L. Miller, S.M. Norton, J. 
Weatherly,* S. Bishop,* B. Cross, K. Nuss, M. Surgenor, Y. Wood. Carolinas Medical 
Center Family Practice, Charlotte, NC: K. Andrews,* T. Barringer, C. Hoffman,* J. 
Konen,* C. Morris, P. Tochiki,* G. Reinblatt, P. Bruner.* Robeson Health Care 
Corporation, Fairmont Clinic, Fairmont, NC: R. Peace, D.O. Stuart,* J. Strickland, L. 
Cummings, D. Craig,* J. Stanfield.* Robeson Health Care, Julian T. Pierce Clinic, 
Pembroke, NC: R. Peace, D.O. Stuart,* J. Strickland, L. Cummings, D. Craig,* J. 
Stanfield.* Wake Forest University School of Medicine, Departments of Internal Medicine 
and Endocrinology, Winston-Salem, NC: J.R. Crouse, L. Menon, S. Marion,* D. Davis,* B. 
Cabrera,* J. Calles, T. Chandler, J. Ellis, E. Kouba, P. Riddle, E. Myers.* Tulane University 
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Health Science Center, New Orleans: V. Fonseca, R.H. McDuffie, N.O. Asafu-Adjaye, S.M. 
Leger, P. Reilly, G. Afner, F. Arrey,* S. Asnani, E. Borshard,* D. Boyd,* A. Cemo, S. 
Chennur,* P. Dupart, R. Garg,* G.P. Girindra,* B. Gouda,* W. Itoua-N’Ganongo,* I. 
Innocent-Ituah,* C. Johnson,* N. Kuhadiya, M. Kukreja,* I. Mangan-Mbondi,* S. Mason,* 
C. McLain, J. Naylyanya,* K. Nazereth,* S. Nazereth,* S. Singh, T. Thethi, K. Varnado,* 
R. Williams.* Kaiser Permanente, Clinic Atlanta Crescent Medical Center, Tucker, GA: J.I. 
Barzilay, M. Eley,* K. Bader, D. Curry-Ball, S. Goodman,* M. Stevens. Veterans Affairs 
(VA) Clinical Center Network: Memphis VA Medical Center, Memphis, TN: W.C. 
Cushman, T.S. Geraci, S.M. Walsh, L.G. Coley, M.B. Elam, C.M. Huff, D.I. Pickering,* P. 
Massimino.* VA Clinical Sites: Memphis VA Medical Center, Hypertension/Lipid 
Research Clinic, Memphis, TN: M.B. Elam, C.W. Thompson, L. Lichtermann, S. Peeples, J. 
Turner-Bates,* M. Heimberg, D. Childress, S. Solomon, J. Turner, J. Jasper, R. Pfeifer, J. 
Coley. Baltimore VA Medical Center, Baltimore: B.P. Hamilton, J. Hamilton, G. Kuzbida, 
D. Bannerman-Wood,* W. Hatten, Jr., A. Lancaster, H. Jang. Carl T. Hayden VA Medical 
Center, Phoenix, AZ: J. Felicetta, M. Bourne-Collo, M.E. Svoboda, D. Clothier, M. Deitz,† 
C. Flaugher,* P. Hayward,* T. Scheibe,* D. Heritage,* S. Velarde, S. Heritage, J.P. Nelson. 
Atlanta VA Medical Service, Decatur, GA: M.E. Sweeney, D. Harrelson, S. McConnell, 
C.R. Rice,* F. Watson, R. Johnson, L. Whittington, M. Nanes, M. Salles. Ralph H. Johnson 
VA Medical Center, Primary Care, Charleston, SC: J. Basile, D.B. Ham, B. North-Lee, H.A. 
Baig, S.U. Rehman, J. Mixson, D. Nelson.* G.V. Montgomery VA Medical Center, 
Research Department, Jackson, MS: K.A. Kirchner, B.S. Ross, M. Kazi,* J. Subauste,* L.A. 
Hinton, L. Mack, B. James,* A. Spencer, L. Henegar,* A. Jones. VA NY Harbor Healthcare 
System, New York: L. Katz, E.A. Richardson, A.G. Goldberg,* A. Nieves, J.E. Russo,* S.A. 
Sochalski, D. Hoffman. Washington VA Medical Center, Washington, DC: V. 
Papademetriou, P. Narayan,* D. Wojciechowski, B. Gregory, R. Alignay,* E. Nylen, B. 
Rajendran, R. Hodges, A. Ross,* A. Notargiacomo.* St. Louis VA Medical Center, St. 
Louis: S. Giddings, E. Clark, A. Pittler, R. Davis, P. Harris, T. Hofmeister. Central Arkansas 
Clinic Healthcare System, Little Rock: D.L. Simmons, J.J. Cooper,* K. Dishongh,* P. 
Choksi,* S. Elbein, F. Faas, Z. Hamid, J. Johnson, A. Mayo,* M.S. Moriarty, D. Rani,* N. 
Rasouli, K. Watson, A. Makdissi. ACCORD Steering Committee Chair: W.T. 
Friedewald, Mailman School of Public Health and Columbia University College of 
Physicians and Surgeons, New York. Coordinating Center: Wake Forest University 
School of Medicine, Winston-Salem, NC: R.P. Byington, W.T. Ambrosius, R.T. Anderson,* 
J. Barnes, J. Beal, C. Bell, D.E. Bonds, S. Burton,* C. Collins, D. Cook, B. Craven, T. 
Craven, D. Dunbar, G.W. Evans, P. Feeney, C.D. Furberg, C.M. Greven, J. Griffin, L. 
Harvin, J. Hepler, L. Howard,* L.T. Howard-Perdue, M. Hough, W. Hwang, A. Kimel, D. 
Lefkowitz, A. Lopina,* J. Lovato, L.C. Lovato, M.E. Miller, D. Reboussin,* S. Rushing, L. 
Sanders, L. Sims, C. Stowe, M. Walkup,* S. Wilmoth, K. Wilson, N. Woolard. Drug 
Distribution Center: Albuquerque VA Medical Center, Albuquerque, NM: D. Raisch, R. 
Ringer, M. Sather, B. DelCurto, D. Garnand. ECG Reading Center: Wake Forest 
University School of Medicine, Winston-Salem, NC: R. Prineas, C. Campbell, Z. Zhang, L. 
Selph, S. Hall,* S. Hensley, Y. Li, M. Mills. Central Chemistry Laboratory: Northwest 
Lipid Research Laboratories, Seattle: S. Marcovina, J. Chmielewski, K. Gadbois, V. Gaur, 
G. Strylewicz, M. Ramirez, S. Waddell, M. Mehan.* ACCORD–MIND MRI Reading 
Center: University of Pennsylvania, Philadelphia: R.N. Bryan, C. Davatzkios, G. Moonis, 
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L. Desiderio, S. D’Arcy.* Fundus Photograph Reading Center: University of Wisconsin 
Medical School, Madison: M. Davis, R. Danis, S. Johnson,* N. Robinson, L. Hubbard, B. 
Esser, D. Thayer, M. Neider, K. Glader, M. Burger. Project Office: National Heart, Lung, 
and Blood Institute, Bethesda, MD: D.G. Simons-Morton, L. Cooper,* M. Domanski, C. 
Nwachuku,* Y. Rosenberg, M. Salive,* P. Savage, J.L. Fleg, J.A. Cutler, N. Geller, D. 
Follmann,* M. Proschan,* C. Jennings, E. Schaeffer,* P. Mills,* J. Bittner,* R. Kirby, P. 
Frommer,† L. Fine, J. Chan. National Institute of Diabetes and Digestive and Kidney 
Diseases, Bethesda, MD: J. Fradkin, S. Malozowski, C. Meyers, T. Hostetter.* National 
Institute on Aging, Bethesda, MD: L. Launer. National Eye Institute, Bethesda, MD: E.Y. 
Chew. Centers for Disease Control and Prevention, Atlanta: A. Albright, K.M.V. Narayan, 
M. Engelgau,* P. Zhang.
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Figure 1. Median Glycated Hemoglobin Levels at Each Study Visit
I bars denote interquartile ranges.
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Figure 2. Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause
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Figure 3. Hazard Ratios for the Primary Outcome and Death from Any Cause in Prespecified 
Subgroups
Data regarding glycated hemoglobin levels at baseline are presented for 10,288 patients 
because a baseline level was not available for 23 patients. Horizontal bars represent the 95% 
confidence interval, and vertical dashed lines indicate the overall hazard ratio. The size of 
each square is proportional to the number of patients.
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Characteristics of the Patients at Baseline.*
Variable Intensive Therapy (N = 5128) Standard Therapy (N = 5123)
Age (yr) 62.2±6.8 62.2±6.8
Female sex (%) 38.7 38.4
Median duration of diabetes (yr) 10 10
Previous cardiovascular event (%) 35.6 34.8
Previous congestive heart failure (%) 4.9 4.8
Race or ethnic group (%)†
 White 64.4 64.5
 Black 19.7 18.9
 Hispanic 7.0 7.4
Education (%)
 Less than high school 15.7 14.0
 High-school graduate 26.1 26.7
 Some college 32.7 32.9
 College degree or higher 25.5 26.4
Cigarette-smoking status (%)
 Current 14.3 13.7
 Former 44.4 44.0
 Never 41.3 42.3
Weight (kg) 93.5±18.7 93.6±18.7
Body-mass index 32.2±5.5 32.2±5.5
Waist circumference (cm) 106.8±14.3 106.8±13.8
Blood pressure (mm Hg)
 Systolic 136.2±17.0 136.5±17.2
 Diastolic 74.8±10.6 75.0±10.7
Medications (%)
 Insulin 34.1 35.7
 Metformin 59.7 60.0
 Any sulfonylurea 50.8 49.4
 Any thiazolidinedione 19.5 19.2
 Any antihypertensive agent 84.9 86.0
 Angiotensin-converting–enzyme inhibitor 53.0 53.0
 Aspirin 54.8 54.1
 Beta-blocker 28.7 29.9
 Any thiazide diuretic 26.5 26.4
 Statin 61.7 62.4
Glycated hemoglobin (%)














Variable Intensive Therapy (N = 5128) Standard Therapy (N = 5123)
 Mean 8.3±1.1 8.3±1.1
 Median 8.1 8.1
Fasting serum glucose (mg/dl) 174.9±56.0 175.7±56.5
Cholesterol (mg/dl)
 Total 183.3±42.1 183.3±41.6
 Low-density lipoprotein 104.9±34.0 104.9±33.8
 High-density lipoprotein
  Women 47.2±13.0 46.9±12.2
  Men 38.4±9.5 38.8±9.8
Median triglyceride (mg/dl) 156 154
Potassium (mg/dl) 4.5±0.4 4.5±0.7
Serum creatinine (mg/dl) 0.9±0.2 0.9±0.2
*
Plus–minus values are means ±SD. There were no significant differences between the two study groups at baseline. The body-mass index is the 
weight in kilograms divided by the square of the height in meters. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To 
convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, 
multiply by 0.01129. To convert the values for potassium to millimoles per liter, multiply by 0.2558. To convert the values for creatinine to 
micromoles per liter, multiply by 88.4.
†
Race was self-reported, and patients could check multiple categories.
















Drug Class and Name Intensive Therapy (N = 5128) Standard Therapy (N = 5123)
no. of patients (%) person-years no. of patients (%) person-years
Single class
Metformin 4856 (94.7) 14,444 4452 (86.9) 12,693
Secretagogue† 4443 (86.6) 12,021 3779 (73.8) 10,059
  Glimepiride 4010 (78.2) 9,142 3465 (67.6) 8,955
  Repaglinide 2574 (50.2) 4,447 908 (17.7) 1,293
Thiazolidinedione‡ 4702 (91.7) 12,844 2986 (58.3) 6,719
  Rosiglitazone 4677 (91.2) 12,639 2946 (57.5) 6,563
α-Glucosidase inhibitor§ 1191 (23.2) 941 263 (5.1) 200
Incretin¶ 911 (17.8) 566 251 (4.9) 175
  Exenatide 622 (12.1) 415 204 (4.0) 155
Any insulin 3965 (77.3) 11,902 2837 (55.4) 7,842
Any bolus insulin 2834 (55.3) 6,806 1794 (35.0) 4,336
Combination of classes
No. of classes without insulin
  1 or 2 2798 (54.6) 2,011 3224 (62.9) 6,612
  3 3030 (59.1) 3,681 1681 (32.8) 2,545
  4 or 5 539 (10.5) 332 109 (2.1) 67
No. of classes with insulin
  0 916 (17.9) 829 892 (17.4) 1,495
  1 or 2 3311 (64.6) 6,603 2375 (46.4) 5,284
  3 2668 (52.0) 4,126 834 (16.3) 1,027
  4 or 5 526 (10.3) 344 64 (1.2) 36
*
Metformin, glimepiride, repaglinide, rosiglitazone, acarbose, and exenatide were provided by a study-supervised formulary. Patients could receive 
more than one medication or combination of medications and may therefore be counted in more than one category. All individual medications that 
are listed were prescribed to at least 10% of patients in either group.
†
Patients received glimepiride, glyburide, gliclazide, repaglinide, or nateglinide.
‡
Patients received rosiglitazone or pioglitazone.















All the patients in this category received acarbose except one who received miglitol.
¶
Patients received exenatide or sitagliptin.





















(N = 5123) P Value†
Adverse events
Hypoglycemia — no. (%)
  Requiring medical assistance 538 (10.5) 179 (3.5) <0.001
  Requiring any assistance 830 (16.2) 261 (5.1) <0.001
Fatal or nonfatal heart failure — no. (%) 152 (3.0) 124(2.4) 0.10
Motor vehicle accident in which patient was driver —
   no./total no. (%) 9/5033 (0.2) 14/5036 (0.3) 0.40
Any nonhypoglycemic serious adverse event — no. (%) 113 (2.2) 82 (1.6) 0.03
Fluid retention — no./total no. (%)‡ 3541/5053 (70.1) 3378/5054 (66.8) <0.001
Clinical measures
Weight gain >10 kg since baseline — no./total no. (%) 1399/5036 (27.8) 713/5042 (14.1) <0.001
Alanine aminotransferase >3 times ULN — no./total no. (%)§ 51/5065 (1.0) 77/5061 (1.5) 0.02
Low-density lipoprotein cholesterol — mg/dl¶ 90.8±33.5 90.6±34.0 0.74
Blood pressure — mm Hg¶
  Systolic 126.4±16.7 127.4±17.2 0.002
  Diastolic 66.9±10.5 67.7±10.6 <0.001
Cigarette-smoking status — no. (%) ∥ 0.54
  Current (previous 30 days) 505 (9.8) 508 (9.9)
  Former 2524 (49.2) 2467 (48.2)
  Never 2093 (40.9) 2143 (41.8)
  Missing data 6 (0.1) 5 (0.1)
Use of nonglycemic medication — no./total no. (%)
  Antihypertensive 4664/5127 (91.0) 4714/5123 (92.0) 0.06
  Angiotensin-converting–enzyme inhibitor 3512/5038 (69.7) 3621/5037 (71.9) 0.02
  Aspirin 3736/4950 (75.5) 3753/4970 (75.5) 0.98
  Beta-blocker 2395/5038 (47.5) 2450/5037 (48.6) 0.27


















(N = 5123) P Value†
  Statin 4432/5039 (88.0) 4425/5054 (87.6) 0.54
*
Plus–minus values are means ±SD. Data within categories are not mutually exclusive. Percentages may not total 100 because of rounding. ULN 
denotes upper limit of the normal range.
†
P values were calculated with the use of Fisher’s exact test or a two-sample t-test.
‡
Of the patients with fluid retention, 89% had pretibial edema or ankle swelling, 30% had shortness of breath, 12% had congestive heart failure or 
pulmonary edema, and 24% had nocturia.
§
The ULN for alanine aminotransferase was 65 U per liter for men and 50 U per liter for women.
¶
Data were obtained from last available measurement at the 12-month visit or later.
∥
Smoking status was reported at the last annual visit.















Primary and Secondary Outcomes.*
Outcome Intensive Therapy (N = 5128) Standard Therapy (N = 5123)
Hazard Ratio
(95% CI) P Value
no. of patients (%) % per yr no. of patients (%) % per yr
Primary outcome 352 (6.9) 2.11 371 (7.2) 2.29 0.90 (0.78–1.04) 0.16
Secondary outcome
 Death
  Any cause 257 (5.0) 1.41 203 (4.0) 1.14 1.22 (1.01–1.46) 0.04
  Cardiovascular causes 135 (2.6) 0.79 94 (1.8) 0.56 1.35 (1.04–1.76) 0.02
 Nonfatal myocardial infarction 186 (3.6) 1.11 235 (4.6) 1.45 0.76 (0.62–0.92) 0.004
 Nonfatal stroke 67 (1.3) 0.39 61 (1.2) 0.37 1.06 (0.75–1.50) 0.74
 Fatal or nonfatal congestive heart
   failure 152 (3.0) 0.90 124 (2.4) 0.75 1.18 (0.93–1.49) 0.17
Causes of death
 Any 257 (5.0) 1.41 203 (4.0) 1.14 1.22 (1.01–1.46) 0.04
 Unexpected or presumed cardio-
   vascular disease†
86 (1.7) 67 (1.3)
 Fatal myocardial infarction† 19 (0.4) 13 (0.3)
 Fatal congestive heart failure† 23 (0.4) 16 (0.3)
 Fatal procedure†
  For cardiovascular disease 10 (0.2) 3 (0.1)
  For noncardiovascular disease 1 (<0.1) 3 (0.1)
 Fatal arrhythmia† 4 (0.1) 10 (0.2)
 Fatal stroke† 9 (0.2) 11 (0.2)
 Other cardiovascular disease† 8 (0.2) 10 (0.2)
 Cancer 65 (1.3) 63 (1.2)
 Condition other than cancer or
   cardiovascular disease‡
50 (1.0) 35 (0.7)
 Undetermined 7 (0.1) 11 (0.2)
*
The primary outcome was the first occurrence of nonfatal myocardial infarction or nonfatal stroke or death from cardiovascular causes. Data 
within categories are not mutually exclusive, and patients who were classified as having more than one possible cause of death are listed in the 
relevant categories. Hazard ratios are for the intensive-therapy group as compared with the standard-therapy group.
†
This condition was a component of the outcome of fatal cardiovascular disease.
‡
Additional details are provided in the Supplementary Appendix.
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